Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
E. Tan
No relevant relationships to disclose
K. Park
No relevant relationships to disclose
W. T. Lim
No relevant relationships to disclose
M. Ahn
No relevant relationships to disclose
Q. S. Ng
No relevant relationships to disclose
J. S. Ahn
No relevant relationships to disclose
D. S. Tan
No relevant relationships to disclose
J. Sun
No relevant relationships to disclose
J. Jac
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. Han
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
F. C. Payumo
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. Credi
Stock Ownership - AVEO
K. McKee
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. M. Cotreau
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
P. Bhargava
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
W. Slichenmyer
Employment or Leadership Position - AVEO
Stock Ownership - AVEO